As Novartis Completes Deal For Nestle's Share In Alcon, Value Of Synergies Is At Stake
This article was originally published in The Pink Sheet Daily
Executive Summary
Independent shareholders, feeling short-changed by Novartis' offer, say the company isn't properly valuing the benefits of joining forces.
You may also be interested in...
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
As the Swiss drug giant builds a massive ophthalmology franchise, Alcon minority shareholders are pushing for a better deal.